B+
Bull case
20%
Probability
Target price
$4.60
Analysis reference price unavailable
Analysis 2026-01-01 · RankAlpha Sentiment AI
PYXS
Pyxis OncologyFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Positive topline plus at least one partnership or non-dilutive deal that meaningfully de-risks the pipeline and triggers multiple expansion among small-cap oncology peers. Valuation rationale: Bull = $4.60 is set as ~4.0x the ANCHOR and is expected over ~12 months if a positive Phase 1 topline (primary short catalyst) is followed by a BD deal/IND advancement (long catalyst); small-cap oncology precedents show 3–5x re-ratings on this sequence [#PR-2025-09-12][#10Kp5].
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.0.
What can break
Binary clinical readouts (high upside or catastrophic downside)
Momentum
91
Value
41
Sentiment
3
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.15 · Bull $4.60 · Bear $0.29Analysis 2026-01-01; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-10 • Model: HYBRID_IC_RP
AI Memo
As of 2026-01-01 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-09-10
Investment thesis
As of 2026-09-10
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-10. Definitions
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $8.44
Why
Momentum91 · Δ7d +2.2
Value41 · Δ7d -0.0
Sentiment3 · Δ7d +1.1
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Value remains the lead driver in the composite, 7D delta -0.0.
Contradictions & invalidation
- • Binary clinical readouts (high upside or catastrophic downside)
- • Limited cash runway and dependency on partners
- • Negative clinical readout or large dilutive financing needs that sharply reduce equity value and investor appetite, pushing shares toward sub-$0.30 outcomes.
Catalyst clock
2026-04-01
Topline Phase 1 readout for lead asset
Lead driver: Value · See fundamentals
Momentum
91
9% active weight
Current posture
7d trendImproving
Δ7d
+2.2
Δ21d
-4.5
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.1
Sentiment
3
62% active weight
Current posture
7d trendImproving
Δ7d
+1.1
Δ21d
+1.1
Why this grade
Composite grade F. Momentum 90.8 / Value 41.2 / Sentiment 2.7
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-01-01. Scenario method
Most likely
B
Base case
60%
Probability
Target price
$1.15
Analysis reference price unavailable
Analysis 2026-01-01 · RankAlpha Sentiment AI
B-
Bear case
20%
Probability
Target price
$0.29
Analysis reference price unavailable
Analysis 2026-01-01 · RankAlpha Sentiment AI
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$251.89M
Beta
1.45
Shares Out
83.41M
P/E (TTM) · Derived
-2.4
P/S (TTM)
26.72
P/FCF (TTM) · Derived
-2.81
Rev YoY
-100.0%
EPS YoY
+33.6%
Gross Margin
+40.5%
Op Margin
-3765.7%
Net Debt
-$49.66M
Current Ratio
1.34
As of 2026-09-10 • Updated nightlySource: Internal modelMethods & Data